Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00519194 · ClinicalTrials.gov registry record · NA
CONcomitant eValuation of Epicor Left atRial Therapy for AF
A NA study, sponsored by Abbott Medical Devices.
- Terminated
- Registry status
- NA
- Development phase
- 112
- Enrollment target
NCT00519194: Clinical Trial NA study, sponsored by Abbott Medical Devices.
NCT00519194 is a NA study that was terminated before completion, run by Abbott Medical Devices. The registered enrollment target is 112 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00519194, a NA study, was terminated before completion, sponsored by Abbott Medical Devices.
- TERMINATED
- Registry status
- NA
- Development phase
- 112 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and efficacy of the Epicor LP Cardiac Ablation System for treating permanent atrial fibrillation during concomitant open chest and/or open heart surgery for one of more of the following procedures: mitral valve repair or replacement, aortic valve repair or replacement, tricuspid valve repair or replacement, coronary artery bypass surgery or patent foramen ovale (PFO closure).
Primary Outcome
Freedom from atrial fibrillation (AF) at 6 months in absence of any AF therapies.
Interventions
- DEVICE Epicor LP Cardiac Ablation System
- PROCEDURE Surgical ablation of permanent AF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2009-04 |
| Est. Completion | 2013-03 |
| Phase | NA |
Why NCT00519194 stopped before completion
NCT00519194 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Epicor LP Cardiac Ablation System is the first listed.
NCT00519194 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00519194 about?
NCT00519194 is a clinical study titled "CONcomitant eValuation of Epicor Left atRial Therapy for AF". The purpose of this study is to test the safety and efficacy of the Epicor LP Cardiac Ablation System for treating permanent atrial fibrillation during concomitant open chest and/or open heart surgery for one of more of the following procedures: mitral valve repair or replacement, aortic valve repai...
What is the current status of trial NCT00519194?
This trial is currently terminated. It is a NA study. The enrollment target is 112 participants. The study started on 2009-04. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00519194?
The interventions under investigation include: Epicor LP Cardiac Ablation System (DEVICE), Surgical ablation of permanent AF (PROCEDURE).
Who is sponsoring clinical trial NCT00519194?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00519194's enrollment target sits among peer trials
112 813th of 2000 higher than 1,185 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia